Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Erdafitinib

e3c07935-4cac-5700-86c4-039675beb038 · FDA Approved · targets FGFR1

Erdafitinib

MeasuredReference

Erdafitinib targets FGFR3, FGFR2, FGFR1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

FGFR3FGFR2FGFR1FGFR4C_KIT

Top hallmarks

  • tumor promoting inflammation3.7k
  • proliferation3.2k
  • evading apoptosis3.1k

Top pathways disrupted

  • apical junction8.6k
  • pi3k akt mtor signaling8.1k
  • allograft rejection7.9k

Resistance landscape — Erdafitinib

MeasuredReference

10 known oncogenic variants exist on Erdafitinib's top targets — see detail for inhibition impact.

Open in new tab